Skip to content

Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment

Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment - EPILOGUE

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04343339
Acronym
EPILOGUE
Enrollment
100
Registered
2020-04-13
Start date
2020-04-08
Completion date
2020-09-30
Last updated
2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addiction, Substance, COVID-19

Keywords

Risk of overdose on de-confinment, COVID-19 containment will change drugs practices, COVID-19 containment will changes access to care, Addiction is a common disease, Alcohol, Containment, Drug use

Brief summary

The current containment linked to COVID-19 will have consequences for people suffering from addiction and there is a risk of overdoses when the containment ends. So the investigators hypothesize that this health crisis is an opportunity to develop risk reduction and access to care for vulnerable people who lives with an addiction. The main objective of this study is to describe the changes in the psychoactive substances consumption during the containment in people suffering from addiction. The secondary objectives are to describe the evolution at 1 month from the end of the containment of problematic consumption and the level of access to care of these users

Interventions

None listed

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \>18 years * Accept study * live with an addiction

Exclusion criteria

\- not being able to answer the questionnaire

Design outcomes

Primary

MeasureTime frameDescription
Evolution of consumption1 daymeasurement of the difference in drugs consumption caused by containment (delta)

Secondary

MeasureTime frameDescription
health care access1 daynumber of drug users referred to care (%)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026